Loading
Life sciences · Journal article
Bioactive Materials · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The efficacy of cancer vaccines depends on spatiotemporally coordinated innate immune priming and antigen cross-presentation, but this hierarchy remains difficult to control with existing delivery platforms. Here, we report a fluorinated diethylenetriamine-modified poly(aspartic acid) nanovaccine platform, termed DET-F, and identify DET-F30 as the optimized formulation for antigen delivery and immune activation. Perfluorooctyl side chains promote early endosomal toll-like receptor 3 (TLR3) associated innate immune signaling and dendritic cell maturation, whereas the pH-responsive polymer backbone facilitates subsequent endosomal escape and cytosolic antigen release. This chemically encoded sequence enables delayed yet enhanced antigen cross-presentation in mature dendritic cells. DET-F30/antigen nanoparticles display efficient antigen loading and cellular uptake, activate TLR3-related innate immune pathways, and elicit robust antigen-specific CD8 + T cell immunity. In multiple tumor models, DET-F30-based vaccination suppresses tumor growth and metastasis, prolongs survival, and enhances post-surgical anti-PD-1 therapy. This work establishes fluorinated poly(amino acid)s as minimalist self-adjuvant nanovaccine vectors and demonstrates that precise polymer-architecture encoding can orchestrate sequential innate immune activation and antigen processing for improved cancer immunotherapy.